Clinical trial NCT05757492: Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Official title: A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CHS-006, as Monotherapy and in Combination With Toripalimab, in Participants With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Advanced Solid Tumor
Non-Small Cell Lung Cancer
Hepatocellular Carcinoma
Keywords: TIGIT inhibitor
PD-1 inhibitor
Advanced Solid Tumor
Lead sponsor: Coherus Biosciences, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Medpace, Inc.
name: Shanghai Junshi Bioscience Co., Ltd.
First posted: 2023-03-07
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: This is a Phase 1, open-label, multiple-phase, multiple phase study. Participants within the advanced solid tumor dose optimization phase will be assigned to one of two dosing arms. After one CHS-006 dose has been selected from Phase 1, Phase 2 participants will be dosed with that dose in combination with toripalimab.
Primary purpose: TREATMENT

Brief summary: This phase 1 open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CHS-006 in combination with toripalimab in 2 phases. Phase 1 (Dose Optimization phase) will explore 2 different dose combinations in participants with advanced/metastatic solid tumors (except pancreatic) and Phase 2 (Indication-specific Expansion phase) will use one selected dose in specific tumor types (non-small cell lung cancer-non squamous \[NSCLC-NS\] and Hepatocellular carcinoma \[HCC\])

Detailed description: The Dose Optimization phase will enroll participants with advanced/metastatic solid tumors (except pancreatic). Up to 20 participants will be randomized into two dosing arms. Two different primary advanced solid tumors have been selected for investigation of antitumor activity in the Indication-specific Expansion phase. Up to 40 participants will be enrolled into each Indication-specific Expansion phase cohort. All participants in both phases will receive CHS-006 in combination with toripalimab intravenously (IV) every 3 weeks (Q3W).

Eligibility criteria: Inclusion Criteria:

* Males and females, ≥18 years old;
* Histopathologically or cytologically confirmed advanced solid tumor (except pancreatic) with disease progression after at least 1 prior line of standard therapy (Dose Optimization phase);
* Tumor-specific criteria (Indication-specific Expansion phase):
* NSCLC-NS (without sensitizing EGFR/ALK/ROS-1/MET mutations) 2nd line plus (2L+): has received and progressed on at least 1 prior chemotherapy regimen. Prior treatment with both anti-PD-1 therapy and platinum-based chemotherapy either concurrently or sequentially are eligible.
* Hepatocellular carcinoma (HCC) 2L+: has received and progressed on at least 1 prior anticancer regimen. Participants with prior treatment with an anti-PD-1 or PD-L1 agent are eligible.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and expected survival ≥12 weeks;
* At least 1 measurable lesion per RECIST v1.1;
* Adequate organ and marrow function

Exclusion Criteria:

* Current or prior use of systemic anticancer therapy, including but not limited to chemotherapy, immunotherapy, biologic therapy, hormone therapy, and targeted therapy, within 28 days prior to the 1st dose of CHS-006;
* NSCLC participants with genomic mutations (e.g., EGFR, ALK, ROS-1, MET, etc.) for which FDA-approved targeted therapies are available or require progression on appropriate prior to enrollment;
* Prior exposure to monoclonal antibodies (mAbs) targeting TIGIT or any of its ligands, including CD155, CD112, or CD113;
* Major surgery within 28 days prior to the 1st dose of CHS-006 or still recovering from prior surgery;
* Symptomatic or untreated central nervous system (CNS) metastases;
* Use of therapeutic immunosuppressive medication within 28 days prior to the 1st planned dose of CHS-006;
* Receipt of live, attenuated vaccination within 30 days prior to the 1st dose of CHS- 006;
* History of active autoimmune disease within the past 2 years, with the following exceptions: vitiligo, alopecia, endocrinopathies controlled by hormone replacement therapy, rheumatoid arthritis and other arthropathies that have not required immunosuppression other than nonsteroidal anti-inflammatory agents, celiac disease controlled by diet, or psoriasis controlled with topical medication;
* Participants with another active solid tumor that has not been curatively treated.

Primary outcomes:
measure: Assessment of the number of participants with treatment-emergent adverse events (TEAEs) receiving CHS-006 administered in combination with toripalimab
timeFrame: Day 1 of study treatment through up to 90 days post last dose of study treatment
Secondary outcomes:
measure: Description of the PK profile of CHS-006 in combination with toripalimab
timeFrame: Measured at multiple timepoints from Day 1 of study treatment through up to 90 days post last dose of study treatment
measure: Immunogenicity of CHS-006 and/or toripalimab
timeFrame: Measured at multiple timepoints from Day 1 of study treatment through up to 90 days post last dose of study treatment
measure: Objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 assessed by the investigator
timeFrame: Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study
measure: Duration of response (DoR) using RECIST v1.1 assessed by the investigator
timeFrame: Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study
measure: Disease control rate (DCR) using RECIST v1.1 assessed by the investigator
timeFrame: Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study
measure: Time to response (TTR) using RECIST v1.1 assessed by the investigator
timeFrame: Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study
measure: Progression-free survival (PFS) using RECIST v1.1 assessed by the investigator
timeFrame: Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study
measure: Overall survival (OS) using RECIST v1.1 assessed by the investigator
timeFrame: Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study
Other outcomes:
Locations:
city: Orlando
country: United States
facility: University of Florida Health Cancer Center
state: Florida
city: Detroit
country: United States
facility: Barbara Ann Karmanos Cancer Institute
state: Michigan
city: Reno
country: United States
facility: Renown Institute for Cancer
state: Nevada
city: Canton
country: United States
facility: Gabrail Cancer and Research Center
state: Ohio
Study officials:
References: